Since the first approval of bevacizumab for treatment of metastatic colorectal cancer (Hurwitz et al, 2004), anti‐angiogenic therapy targeting the VEGF signaling pathway has been approved for a number of cancer entities (Carmeliet & Jain, 2011; Welti et al, 2013). Here, VEGFA is linked to cancer.